Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
May 22 2024 - 1:23PM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
May,
2024
Commission
File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation
of registrant’s name into English)
8-2-337,
Road No. 3, Banjara Hills
Hyderabad,
Telangana 500 034, India
+91-40-49002900
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual
report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document
that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is
incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country
exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not
required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already
been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
¨ No x
If
“Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
Date: May 22, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit
99.1
|
Dr.
Reddy’s Laboratories Ltd.
8-2-337,
Road No. 3, Banjara Hills,
Hyderabad
- 500 034, Telangana,
India.
CIN
: L85195TG1984PLC004507
Tel
: +91 40 4900 2900
Fax :
+91 40 4900 2999
Email
: mail@drreddys.com
www.drreddys.com |
May 22, 2024
National Stock Exchange of India Ltd. (Scrip Code:
DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Ref: |
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |
This is to inform that the Company has received
an order from GST Authority towards tax demand including interest and penalty. The details as required under Regulation 30 of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015 are as hereunder:
Name of the authority |
: |
The Joint Commissioner of CGST, (Appeals), Indore, (M.P.) |
Nature and details of the action(s) taken, initiated or order(s) passed |
: |
The Company has received appellate order confirming the tax demand including interest and penalty under Section 73 / 50 / 122 (2)(a) of the CGST Act, 2017. |
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority |
: |
Order dated May 20, 2024 was received by the authorized officials of the Company on May 22, 2024. |
Details of the violation(s)/ contravention(s) committed or alleged to be committed |
: |
The appellate authority has rejected our appeal relating to availment of credit in GST return. |
Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible |
: |
The above order levies a penalty of Rs. 2,24,032/-. Based on our evaluation, there is no material impact on the financials, operations, or other activities of the Company. |
The Company will evaluate filing necessary appeal
with the appellate authority in this regard.
This is for your information and records.
Thanking you,
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer &
Head-CSR
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From May 2024 to Jun 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Jun 2023 to Jun 2024